尾-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells

详细信息    查看全文

• 作者：Xia Fang^a ; ¹ ; ^{dilay_123@yahoo.cn" class="auth_mail} ; Pan Gu^a ; ¹ ; ^{gupanjiayou@sina.com" class="auth_mail} ; Caicun Zhou^c ; ^{cczhou2000@126.com" class="auth_mail} ; Aibin Liang^b ; ^{lab410817@126.com" class="auth_mail} ; Shenxiang Ren^c ; ^{Hillary_ren@126.com" class="auth_mail} ; Fang Liu^a ; ^{GYLIUFANG@HOTMAIL.COM" class="auth_mail} ; Yu Zeng^a ; ^{yuzeng77@hotmail.com" class="auth_mail} ; Yunjin Wu^a ; ^{yunjinwuhope@126.com" class="auth_mail} ; Yinmin Zhao^c ; ^{zhaoyingmin80@126.com" class="auth_mail} ; Binbin Huang^b ; ^{binbin2004_20@hotmail.com" class="auth_mail} ; Zongmei Zhang^a ; ^{zongzong1986@126.com" class="auth_mail} ; Xianghua Yi^a ; ^{yixhxf@yahoo.com.cn" class="auth_mail}
• 关键词：Non-small cell lung cancer ; Epidermal growth factor receptor ; Tyrosine kinase inhibitors ; 尾-catenin ; Gefitinib ; Resistance
• 刊名：Pulmonary Pharmacology & Therapeutics
• 出版年：June 2014
• 年：2014
• 卷：28
• 期：1
• 页码：41-48
• 全文大小：1601 K

文摘

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) presents great challenges in the treatment of non-small cell lung cancer (NSCLC) patients, while the mechanisms are still not well understood. The 尾-catenin signaling pathway has been found to be associated with chemoresistance and can activate the EGFR and its downstream pathways. This study aimed to investigate the role of 尾-catenin in acquired resistance to EGFR-TKIs in NSCLC cell lines.

Methods

The expression and transcriptional activity of 尾-catenin were measured in both the NSCLC cell line PC9 and its sub-line PC9/AB₂ which has acquired resistance to gefitinib. Knockdown and overexpression of 尾-catenin in the PC9/AB₂ and PC9 cells were performed. The cell survival rate and the activation of the EGFR and its downstream pathways were detected in the two cell lines after transfection.

Results

Nuclear translocation of 尾-catenin was increased in the PC9/AB₂ cells and the baseline expression of members of the 尾-catenin signaling pathway was also higher in the PC9/AB₂ cells. Knocking down the expression of 尾-catenin increased the sensitivity of the PC9/AB₂ cells to gefitinib by blocking the activation of the EGFR downstream pathways, while 尾-catenin overexpression improved PC9 cells resistance to gefitinib by enhancing the activation of the EGFR and its downstream signaling.

Conclusion

尾-catenin plays an important role in acquired resistance to EGFR-TKIs in NSCLC cell lines and may be a potential therapeutic target for NSCLC patients who have failed to respond to targeted therapy.